Quick Takeaways
- AVLN - Avalyn Pharma Inc. has 16 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 16 Insiders of Avalyn Pharma Inc.
- Symbol
- AVLN
- Location
- Boston, MA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 10 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Avalyn Pharma Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Adam H. Golden | General Counsel | Mixed | 29 Apr 2026 | |||
| Lyn Baranowski | Chief Executive Officer, Director | Mixed | 29 Apr 2026 | |||
| Douglas R. Carlson | Chief Financial Officer | Mixed | 29 Apr 2026 | |||
| Kate Haviland | Director | Mixed | 29 Apr 2026 | |||
| Howard Lazarus | Chief Medical Officer | Mixed | 29 Apr 2026 | |||
| Heather D. Turner | Director | Mixed | 29 Apr 2026 | |||
| Melissa Rhodes | Chief Operating Officer | Mixed | 29 Apr 2026 | |||
| David Matthew Friedman | Director | Mixed | 29 Apr 2026 | |||
| Jon Congleton | Director | Mixed | 29 Apr 2026 | |||
| Erin Lavelle | Director | Mixed | 29 Apr 2026 | |||
| Jill Carroll | Director | Mixed | 01 May 2026 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | Mixed | 01 May 2026 | |||
| Simeon George | 10%+ Owner | Mixed | 01 May 2026 | |||
| FMR LLC | Other*, 10%+ Owner | Mixed | 01 May 2026 | |||
| Novo Holdings A/S | 10%+ Owner | Mixed | 01 May 2026 | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | Mixed | 01 May 2026 |
Top shareholders of Avalyn Pharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,883,289
|
— | — | 01 May 2026 | |
| FMR LLC |
3/4/5
|
Other*, 10%+ Owner |
—
class O/S missing
|
2,284,535
|
— | — | 01 May 2026 | |
| Jill Carroll |
3/4/5
|
Director |
—
class O/S missing
|
2,186,562
|
— | — | 01 May 2026 | |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,275,486
|
— | — | 01 May 2026 | |
| Simeon George |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,122,087
|
— | — | 01 May 2026 | |
| SR ONE CAPITAL MANAGEMENT, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,122,087
|
— | — | 01 May 2026 | |
| Lyn Baranowski |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
501,033
|
— | — | 29 Apr 2026 | |
| Adam H. Golden |
3/4/5
|
General Counsel |
—
class O/S missing
|
254,891
|
— | — | 29 Apr 2026 | |
| Douglas R. Carlson |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
211,975
|
— | — | 29 Apr 2026 | |
| Howard Lazarus |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
211,975
|
— | — | 29 Apr 2026 | |
| Melissa Rhodes |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
211,975
|
— | — | 29 Apr 2026 | |
| Erin Lavelle |
3/4/5
|
Director |
—
class O/S missing
|
26,978
|
— | — | 29 Apr 2026 | |
| Heather D. Turner |
3/4/5
|
Director |
—
class O/S missing
|
26,978
|
— | — | 29 Apr 2026 | |
| Jon Congleton |
3/4/5
|
Director |
—
class O/S missing
|
26,978
|
— | — | 29 Apr 2026 | |
| Kate Haviland |
3/4/5
|
Director |
—
class O/S missing
|
26,978
|
— | — | 29 Apr 2026 |
Recent Insider Transactions by Companies or Individuals for Avalyn Pharma Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | AVLN | Voting Common Stock | Purchase | 16.7% | 555,555 | 3,883,289 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Voting Common Stock | Conversion of derivative security | 3,327,734 | 3,327,734 | 01 May 2026 | Direct | |||
| Novo Holdings A/S | AVLN | Series D Preferred Stock | Conversion of derivative security | -100% | -12,558,081 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series C-2 Preferred Stock | Conversion of derivative security | -100% | -5,587,603 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series C-1 Preferred Stock | Conversion of derivative security | -100% | -25,899,284 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series B Preferred Stock | Conversion of derivative security | -100% | -1,986,369 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series A Preferred Stock | Conversion of derivative security | -100% | -18,000,000 | 0 | 01 May 2026 | Direct | ||
| Fmr Llc | AVLN | Common Stock | Conversion of derivative security | 2,284,535 | 2,284,535 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | |||
| Fmr Llc | AVLN | Series D Preferred Stock | Conversion of derivative security | -100% | -377,948 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series C-2 Preferred Stock | Conversion of derivative security | -100% | -225,843 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series C-1 Preferred Stock | Conversion of derivative security | -100% | -872,868 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series B Preferred Stock | Conversion of derivative security | -100% | -80,291 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series A Preferred Stock | Conversion of derivative security | -100% | -727,585 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Jill Carroll | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| Jill Carroll | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| Jill Carroll | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| Jill Carroll | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Purchase | 32.9% | 277,777 | 1,122,087 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Common Stock | Purchase | 32.9% | 277,777 | 1,122,087 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Conversion of derivative security | 844,310 | 844,310 | 01 May 2026 | See Note 4 | |||
| Sr One Capital Management, Llc | AVLN | Common Stock | Conversion of derivative security | 844,310 | 844,310 | 01 May 2026 | See Note 4 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| Sr One Capital Management, Llc | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,560 | 0 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,560 | 0 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -6,827,429 | 0 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -6,827,429 | 0 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Common Stock | Conversion of derivative security | 1,275,486 | 1,275,486 | 01 May 2026 | Direct | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -4,060,259 | 0 | 01 May 2026 | Direct | ||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -20,482,289 | 0 | 01 May 2026 | Direct | ||
| Douglas R. Carlson | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 30 Apr 2026 | Direct | |||
| Erin Lavelle | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 30 Apr 2026 | Direct | |||
| Adam H. Golden | AVLN | Stock Option (Right to Buy) | Award | 254,891 | 254,891 | 29 Apr 2026 | Direct | |||
| Jon Congleton | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Heather D. Turner | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Melissa Rhodes | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 29 Apr 2026 | Direct | |||
| Kate Haviland | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Howard Lazarus | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 29 Apr 2026 | Direct | |||
| Lyn Baranowski | AVLN | Stock Option (Right to Buy) | Award | 501,033 | 501,033 | 29 Apr 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.